Serum Institute of India to use Genticel's Vaxiclase platform to develop pertussis vaccines

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces that it has licensed its Vaxiclase technology to Serum Institute of India Ltd., for use as a component in acellular multivalent combination vaccines including pertussis antigens.



from The Medical News http://ift.tt/1F1HYRi